GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IRLAB Therapeutics AB (OSTO:IRLAB A) » Definitions » Price-to-Free-Cash-Flow

IRLAB Therapeutics AB (OSTO:IRLAB A) Price-to-Free-Cash-Flow : N/A (As of Jun. 20, 2024)


View and export this data going back to 2017. Start your Free Trial

What is IRLAB Therapeutics AB Price-to-Free-Cash-Flow?

As of today (2024-06-20), IRLAB Therapeutics AB's share price is kr13.05. IRLAB Therapeutics AB's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2024 was kr-3.12. Hence, IRLAB Therapeutics AB's Price-to-Free-Cash-Flow Ratio for today is N/A.

The historical rank and industry rank for IRLAB Therapeutics AB's Price-to-Free-Cash-Flow or its related term are showing as below:

During the past 11 years, IRLAB Therapeutics AB's highest Price-to-Free-Cash-Flow Ratio was 19.32. The lowest was 12.33. And the median was 16.78.

OSTO:IRLAB A's Price-to-Free-Cash-Flow is not ranked *
in the Biotechnology industry.
Industry Median: 32.09
* Ranked among companies with meaningful Price-to-Free-Cash-Flow only.

IRLAB Therapeutics AB's Free Cash Flow per Share for the three months ended in Mar. 2024 was kr-0.74. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was kr-3.12.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was -19.20% per year.

During the past 11 years, IRLAB Therapeutics AB's highest 3-Year average Free Cash Flow per Share Growth Rate was -3.70% per year. The lowest was -55.10% per year. And the median was -14.95% per year.


IRLAB Therapeutics AB Price-to-Free-Cash-Flow Historical Data

The historical data trend for IRLAB Therapeutics AB's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IRLAB Therapeutics AB Price-to-Free-Cash-Flow Chart

IRLAB Therapeutics AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Free-Cash-Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 17.80 - -

IRLAB Therapeutics AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Price-to-Free-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of IRLAB Therapeutics AB's Price-to-Free-Cash-Flow

For the Biotechnology subindustry, IRLAB Therapeutics AB's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


IRLAB Therapeutics AB's Price-to-Free-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, IRLAB Therapeutics AB's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where IRLAB Therapeutics AB's Price-to-Free-Cash-Flow falls into.



IRLAB Therapeutics AB Price-to-Free-Cash-Flow Calculation

IRLAB Therapeutics AB's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=13.05/-3.115
=N/A

IRLAB Therapeutics AB's Share Price of today is kr13.05.
IRLAB Therapeutics AB's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-3.12.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

IRLAB Therapeutics AB  (OSTO:IRLAB A) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


IRLAB Therapeutics AB Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of IRLAB Therapeutics AB's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


IRLAB Therapeutics AB (OSTO:IRLAB A) Business Description

Traded in Other Exchanges
Address
Arvid Wallgren Backe 20, Goteborg, SWE, 413 46
IRLAB Therapeutics AB is a drug discovery and development company providing novel treatments for disorders of the brain. The company focuses on innovative treatments and quality of life for patients with neurological and psychiatric illnesses. It is engaged in programs targeting core dysfunctions in Parkinson's disease and dementias. In addition, it is also involved in the clinical development of novel compounds which aims at offering improved clinical benefit for patients with Parkinson's disease. The company's current clinical candidates, mesdopetam (IRL790) and pirepemat (IRL752), both of which have successfully gone through Phase I safety and Phase IIa efficacy proof-of-concept studies, are now in Phase IIb trials.

IRLAB Therapeutics AB (OSTO:IRLAB A) Headlines

No Headlines